

SEATTLE GENETICS INC /WA  
Form SC 13D/A  
February 05, 2018

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13D  
Under the Securities Exchange Act of 1934

(Amendment No. 25)

**Seattle Genetics, Inc.**

(Name of Issuer)

**Common Stock, par value \$0.001 per share**

(Title of Class of Securities)

**812578102**

(CUSIP Number)

**Alexandra A. Toohey**

**Chief Financial Officer**

**Baker Bros. Advisors LP  
860 Washington Street, 3<sup>rd</sup> Floor  
New York, NY 10014**

**(212) 339-5690**

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

**January 31, 2018**

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. "

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 812578102 Page 2 of 12 Pages

NAMES OF REPORTING PERSONS

**1**

Baker Bros. Advisors LP

(a) ..

**2** CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(b) ..

**3** SEC USE ONLY

SOURCE OF FUNDS (See Instructions)

**4**

OO

**5** CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) ..

OR 2(e)

CITIZENSHIP OR PLACE OF ORGANIZATION

**6**

Delaware

SOLE VOTING POWER

**7**

**NUMBER OF** 49,680,229 (1)

**SHARES** SHARED VOTING POWER

**BENEFICIALLY 8**

**OWNED BY** 0

**EACH** SOLE DISPOSITIVE POWER

**REPORTING 9**

**PERSON** 49,680,229 (1)

**WITH** SHARED DISPOSITIVE POWER

**10**

0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**11**

49,680,229 (1)

**12** CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See ..  
Instructions)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

**13**

31.6% (1)(2)

TYPE OF REPORTING PERSON (See Instructions)

**14**

IA, PN

Edgar Filing: SEATTLE GENETICS INC /WA - Form SC 13D/A

(1) Includes 108,520 shares of the Common Stock of Seattle Genetics, Inc. (the “Issuer”) underlying 108,520 options.

(2) Based on 155,341,860 shares of the Issuer’s Common Stock that will be outstanding following the Offering (as defined below) plus 1,730,769 shares issued as part of the Underwriter’s option (as defined below) described in the Issuer’s Prospectus Supplement filed with the Securities and Exchange Commission (the “SEC”) on February 1, 2018.

Page 2 of 12 Pages

CUSIP No. 812578102 Page 3 of 12 Pages

NAMES OF REPORTING PERSONS

**1**

Baker Bros. Advisors (GP) LLC

(a) ..

**2** CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(b) ..

**3** SEC USE ONLY

SOURCE OF FUNDS (See Instructions)

**4**

OO

**5** CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) ..

OR 2(e)

CITIZENSHIP OR PLACE OF ORGANIZATION

**6**

Delaware

SOLE VOTING POWER

**7**

**NUMBER OF** 49,680,229 (1)

**SHARES** SHARED VOTING POWER

**BENEFICIALLY 8**

**OWNED BY** 0

**EACH** SOLE DISPOSITIVE POWER

**REPORTING 9**

**PERSON** 49,680,229 (1)

**WITH** SHARED DISPOSITIVE POWER

**10**

0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**11**

49,680,229 (1)

**12** CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See ..  
Instructions)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

**13**

31.6% (1)(2)

TYPE OF REPORTING PERSON (See Instructions)

**14**

HC, OO

(1) Includes 108,520 shares of the Issuer's Common Stock underlying 108,520 options.

(2) Based on 155,341,860 shares of the Issuer's Common Stock that will be outstanding following the Offering (as defined below) plus 1,730,769 shares issued as part of the Underwriter's option (as defined below) described in the Issuer's Prospectus Supplement filed with the SEC on February 1, 2018.

CUSIP No. 812578102 Page 4 of 12 Pages

NAMES OF REPORTING PERSONS

**1**

Julian C. Baker

(a) ..

**2** CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(b) ..

**3** SEC USE ONLY

SOURCE OF FUNDS (See Instructions)

**4**

OO

**5** CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) ..

OR 2(e)

CITIZENSHIP OR PLACE OF ORGANIZATION

**6**

United States

SOLE VOTING POWER

**7**

**NUMBER OF** 49,818,654(1)

**SHARES** SHARED VOTING POWER

**BENEFICIALLY 8**

**OWNED BY** 0

**EACH** SOLE DISPOSITIVE POWER

**REPORTING 9**

**PERSON** 49,818,654 (1)

**WITH** SHARED DISPOSITIVE POWER

**10**

0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**11**

49,818,654 (1)

**12** CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See ..  
Instructions)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

**13**

31.7% (1)(2)

TYPE OF REPORTING PERSON (See Instructions)

**14**

IN, HC

(1) Includes 108,520 shares of the Issuer's Common Stock underlying 108,520 options.

(2) Based on 155,341,860 shares of the Issuer's Common Stock that will be outstanding following the Offering (as defined below) plus 1,730,769 shares issued as part of the Underwriter's option (as defined below) described in the Issuer's Prospectus Supplement filed with the SEC on February 1, 2018.



CUSIP No. 812578102 Page 5 of 12 Pages

NAMES OF REPORTING PERSONS

**1**  
Felix J. Baker

**2** CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a) ..

(b) ..

**3** SEC USE ONLY

SOURCE OF FUNDS (See Instructions)

**4**  
OO

**5** CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) ..  
OR 2(e)

CITIZENSHIP OR PLACE OF ORGANIZATION

**6**  
United States

SOLE VOTING POWER

**7**  
NUMBER OF 49,818,661 (1)  
SHARES SHARED VOTING POWER

**8** BENEFICIALLY OWNED BY

**9** EACH 0  
SOLE DISPOSITIVE POWER

**10** REPORTING PERSON 49,818,661 (1)  
WITH SHARED DISPOSITIVE POWER

**11**  
0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**12**  
49,818,661 (1)

**13** CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See ..  
Instructions)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

**14**  
31.7% (1)(2)

TYPE OF REPORTING PERSON (See Instructions)

**15**  
IN, HC

(1) Includes 108,520 shares of the Issuer's Common Stock underlying 108,520 options.

(2) Based on 155,341,860 shares of the Issuer's Common Stock that will be outstanding following the Offering (as defined below) plus 1,730,769 shares issued as part of the Underwriter's option (as defined below) described in the Issuer's Prospectus Supplement filed with the SEC on February 1, 2018.

Page 5 of 12 Pages

CUSIP No. 812578102 Page 6 of 12 Pages

NAMES OF REPORTING PERSONS

**1**  
FBB2, LLC

**2** CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a) ..

(b) ..

**3** SEC USE ONLY  
SOURCE OF FUNDS (See Instructions)

**4**  
OO  
**5** CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) ..  
OR 2(e)

**6**  
CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

SOLE VOTING POWER

<b>7</b>	
<b>NUMBER OF</b>	18,243
<b>SHARES</b>	SHARED VOTING POWER
<b>BENEFICIALLY 8</b>	
<b>OWNED BY</b>	0
<b>EACH</b>	SOLE DISPOSITIVE POWER
<b>REPORTING 9</b>	
<b>PERSON</b>	18,243
<b>WITH</b>	SHARED DISPOSITIVE POWER
<b>10</b>	
	0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**11**  
18,243

**12** CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See ..  
Instructions)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

**13**  
(1)

TYPE OF REPORTING PERSON (See Instructions)

**14**  
OO

(1) The percentage of ownership is less than 0.1%, based on 155,341,860 shares of the Issuer's Common Stock that will be outstanding following the Offering (as defined below) plus 1,730,769 shares issued as part of the Underwriter's option (as defined below) described in the Issuer's Prospectus Supplement filed with the SEC on February 1, 2018.

Page 6 of 12 Pages

CUSIP No. 812578102 Page 7 of 12 Pages

NAMES OF REPORTING PERSONS

**1**

FBB3 LLC

(a) ..

**2** CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(b) ..

**3** SEC USE ONLY

SOURCE OF FUNDS (See Instructions)

**4**

OO

**5** CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) ..

OR 2(e)

CITIZENSHIP OR PLACE OF ORGANIZATION

**6**

Delaware

SOLE VOTING POWER

**7**

NUMBER OF 12,678

SHARES SHARED VOTING POWER

**BENEFICIALLY 8**

**OWNED BY 0**

**EACH SOLE DISPOSITIVE POWER**

**REPORTING 9**

**PERSON 12,678**

**WITH SHARED DISPOSITIVE POWER**

**10**

0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**11**

12,678

**12** CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See ..  
Instructions)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

**13**

(1)

TYPE OF REPORTING PERSON (See Instructions)

**14**

OO

(1) The percentage of ownership is less than 0.1%, based on 155,341,860 shares of the Issuer's Common Stock that will be outstanding following the Offering (as defined below) plus 1,730,769 shares issued as part of the Underwriter's option (as defined below) described in the Issuer's Prospectus Supplement filed with the SEC on February 1, 2018.

Page 7 of 12 Pages

**Amendment No. 25 to Schedule 13D**

This Amendment No. 25 to Schedule 13D amends and supplements the statements on the previously filed Schedule 13D, as amended, filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC (the “Adviser GP”), Julian C. Baker, Felix J. Baker, FBB2, LLC (“FBB2”) and FBB3 LLC (“FBB3”) (collectively the “Reporting Persons”). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Each capitalized term used but not defined herein has the meaning ascribed to such term in the Schedule 13D, as amended.

The Adviser GP is the sole general partner of the Adviser. Pursuant to management agreements, as amended, among the Adviser, Baker Brothers Life Sciences, L.P. (“Life Sciences”) and 667, L.P. (“667”, and together with Life Sciences, the “Funds”), and their respective general partners, the Funds’ respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds’ investments and voting power over investments.

**ITEM 2.**

**Identity and Background.**

(a) The Reporting Persons are:

- |    |                 |
|----|-----------------|
| 1. | The Adviser     |
| 2. | The Adviser GP  |
| 3. | Felix J. Baker  |
| 4. | Julian C. Baker |
| 5. | FBB2            |
| 6. | FBB3            |

(b) The business address of each of the Reporting Persons is:

c/o Baker Bros. Advisors LP

860 Washington Street, 3<sup>rd</sup> Floor

New York, NY 10014

(c) The Adviser is an entity engaged in investment activities, and the Adviser GP is in the business of acting as its general partner and, through the Adviser, investment activities. The principal business of each of Julian C. Baker and Felix J. Baker is to serve as a managing member of the Adviser GP. The principal business of FBB2 is to engage in investment activities. Julian C. Baker and Felix J. Baker are the sole managers of FBB2 and by policy they do not transact in or vote the securities of Seattle Genetics, Inc. (the "Issuer") held by FBB2. The principal business of FBB3 is to engage in investment activities. Julian C. Baker and Felix J. Baker are the sole managers of FBB3 and by policy they do not transact in or vote the securities of the Issuer held by FBB3.

(d) and (e) During the past five years, none of the Reporting Persons nor any of the Funds (as defined below) has been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.



(f) The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. FBB2 is a limited liability company organized under the laws of the state of Delaware. FBB3 is a limited liability company organized under the laws of the state of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

### **Item 3. Source and Amount of Funds or Other Consideration.**

Item 3 of Amendment No. 25 is supplemented and amended, as the case may be, as follows:

The disclosure in Item 4 below is incorporated herein by reference.

### **Item 4. Purpose of the Transaction.**

Item 4 of Amendment No. 25 is supplemented and superseded, as the case may be, as follows:

On January 31, 2018, the Issuer entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Barclays Capital Inc., as representatives of the several underwriters listed on Schedule I thereto (the “Underwriters”), related to an underwritten public offering (the “Offering”) of 11,538,461 shares of the Issuer’s Common Stock at a price to the public of \$52.00 per share. In addition, the Issuer granted the Underwriters an option exercisable for 30 days from the date of the Underwriting Agreement to purchase, at the public offering price less any underwriting discounts and commissions, up to an additional 1,730,769 shares of Common Stock to cover overallocments, if any (“Underwriters option”). The Offering is expected to close on February 5, 2018.

Pursuant to the Offering, on February 1, 2018, 667 and Life Sciences purchased 389,610 shares of Common Stock and 3,456,543 shares of Common Stock, respectively, at the offering price of \$52.00 per share. The Funds purchased the shares of the Issuer’s Common Stock with their working capital.

The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons’ continuing assessments of pertinent factors, including the availability of shares of Common Stock or other securities for purchase at particular price levels, the business prospects of the Issuer, other business

investment opportunities, economic conditions, stock market conditions, money market conditions, the attitudes and actions of the board of directors and management of the Issuer, the availability and nature of opportunities to dispose of shares in the Issuer and other plans and requirements of the particular entities. The Reporting Persons may discuss items of mutual interest with the Issuer, which could include items in subparagraphs (a) through (j) of Schedule 13D.

Depending upon their assessments of the above factors, the Reporting Persons or their affiliates may change their present intentions as stated above and they may assess whether to make suggestions to the management of the Issuer regarding financing, and whether to acquire additional securities of the Issuer, including shares of Common Stock (by means of open market purchases, privately negotiated purchases, exercise of some or all of the Stock Options (as defined below), or otherwise) or to dispose of some or all of the securities of the Issuer, including shares of Common Stock, under their control.

Except as otherwise disclosed herein, at the present time, the Reporting Persons do not have any plans or proposals with respect to any extraordinary corporate transaction involving the Issuer including, without limitation, those matters described in subparagraphs (a) through (j) of Item 4 of Amendment No. 25.

## Item 5.

## Interest in Securities of the Issuer.

(a) and (b) Items 7 through 11 and 13 of each of the cover pages of this Amendment No. 25 are incorporated herein by reference. Set forth below is the aggregate number and percentage of shares of Common Stock directly held, as of the date hereof, by each of the following based upon 155,341,860 shares of the Issuer's Common Stock that will be outstanding following the Offering plus 1,730,769 shares issued as part of the Underwriter's option described in the Issuer's Prospectus Supplement filed with the SEC on February 1, 2018. Such percentage figures were calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended.

Holder	Number of Shares	Percentage of Class Outstanding	
667, L.P.	5,220,074	3.3	%
Baker Brothers Life Sciences, L.P.	44,297,235	28.2	%

The Adviser GP, Felix J. Baker and Julian C. Baker as principals of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds, and may be deemed to have the power to vote or direct the vote of and the power to dispose or direct the disposition of such securities.

The Reporting Persons disclaim beneficial ownership of the securities held by each of the Funds, and this Amendment No. 25 shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 13(d) or for any other purpose, except to the extent that any such Reporting Persons actually exercises voting or dispositive power with respect to such securities.

Julian C. Baker and Felix J. Baker are also the sole managers of FBB2 and FBB3 and by policy they do not transact in or vote the securities of the Issuer held by FBB2 and FBB3.

Felix J. Baker is a Director of the Issuer. In connection with his service on the Issuer's Board, Felix J. Baker holds options to purchase Common Stock of the Issuer ("Stock Options"), Common Stock and restricted stock units payable solely in Common Stock of the Issuer ("Restricted Stock") as disclosed in previous amendments to this Schedule 13D.

Felix J. Baker serves on the Issuer's Board as a representative of the Funds. The policy of the Funds and the Adviser does not permit employees of the Adviser to receive compensation for serving as a Director of the Issuer. Therefore, Felix J. Baker has no pecuniary interest in the Stock Options, Common Stock or Restricted Stock. The Funds are

instead entitled to the pecuniary interest in the Stock Options, Common Stock and Restricted Stock.

The Adviser has voting and investment power over the Stock Options, Common Stock underlying such Stock Options, Restricted Stock and Common Stock held by Felix Baker received as directors compensation. The Adviser GP, and Felix J. Baker and Julian C. Baker as principals of the Adviser GP, may be deemed to have the power to vote or direct the vote of and the power to dispose or direct the disposition of the Stock Options, Common Stock underlying such Stock Options, Restricted Stock and Common Stock of the Issuer held by Felix J. Baker received as directors compensation.

Page 10 of 12 Pages

(c) Except as disclosed herein or in any previous amendments to this Schedule 13D, none of the Reporting Persons or their affiliates has effected any other transactions in securities of the Issuer during the past 60 days.

(d) Certain securities of the Issuer are held directly by 667, a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Biotech Capital (GP), LLC.

Certain securities of the Issuer are held directly by Life Sciences, a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Brothers Life Sciences Capital (GP), LLC.

(e) Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 5, 2018

**BAKER BROS.  
ADVISORS LP**

By: Baker Bros. Advisors  
(GP) LLC, its general  
partner

By: /s/ Scott L. Lessing  
Name: Scott L. Lessing  
Title: President

**BAKER BROS.  
ADVISORS (GP) LLC**

By: /s/ Scott L. Lessing  
Name: Scott L. Lessing  
Title: President

/s/ Julian C. Baker  
Julian C. Baker

/s/ Felix J. Baker  
Felix J. Baker

**FBB2, LLC**

By: /s/ Julian C. Baker  
Name: Julian C. Baker  
Title: Manager

**FBB3 LLC**

By: /s/ Julian C. Baker  
Name: Julian C. Baker

Title: Manager

Page 12 of 12 Pages